Biogen, Inc. (BIIB)
250.48
-2.92
(-1.15%)
USD |
NASDAQ |
Nov 12, 16:00
250.69
+0.21
(+0.08%)
After-Hours: 20:00
Biogen Price to Book Value : 1.956 for Nov. 12, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 1.956 |
| November 11, 2026 | 1.979 |
| November 10, 2026 | 1.978 |
| November 09, 2026 | 1.991 |
| November 06, 2026 | 1.940 |
| November 05, 2026 | 1.905 |
| November 04, 2026 | 1.988 |
| November 03, 2026 | 1.944 |
| November 02, 2026 | 1.945 |
| October 30, 2026 | 1.981 |
| October 29, 2026 | 1.95 |
| October 28, 2026 | 1.906 |
| October 27, 2026 | 1.974 |
| October 26, 2026 | 1.970 |
| October 23, 2026 | 1.958 |
| October 22, 2026 | 1.983 |
| October 21, 2026 | 1.882 |
| October 20, 2026 | 1.899 |
| October 19, 2026 | 1.824 |
| October 16, 2026 | 1.817 |
| October 15, 2026 | 1.838 |
| October 14, 2026 | 1.819 |
| October 13, 2026 | 1.788 |
| October 12, 2026 | 1.792 |
| October 09, 2026 | 1.763 |
| Date | Value |
|---|---|
| October 08, 2026 | 1.706 |
| October 07, 2026 | 1.735 |
| October 06, 2026 | 1.741 |
| October 05, 2026 | 1.746 |
| October 02, 2026 | 1.718 |
| October 01, 2026 | 1.740 |
| September 30, 2026 | 1.764 |
| September 29, 2026 | 1.779 |
| September 28, 2026 | 1.792 |
| September 25, 2026 | 1.784 |
| September 24, 2026 | 1.774 |
| September 23, 2026 | 1.783 |
| September 22, 2026 | 1.766 |
| September 21, 2026 | 1.717 |
| September 18, 2026 | 1.689 |
| September 17, 2026 | 1.717 |
| September 16, 2026 | 1.693 |
| September 15, 2026 | 1.694 |
| September 14, 2026 | 1.703 |
| September 11, 2026 | 1.702 |
| September 10, 2026 | 1.688 |
| September 09, 2026 | 1.651 |
| September 08, 2026 | 1.665 |
| September 04, 2026 | 1.730 |
| September 03, 2026 | 1.759 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| AbbVie, Inc. | -- |
| Gilead Sciences, Inc. | 15.99 |
| Amgen, Inc. | 17.60 |
| Regeneron Pharmaceuticals, Inc. | 2.936 |
| Eli Lilly & Co. | 33.36 |
Price to Book Value Related Metrics
| PE Ratio | 107.23 |
| PS Ratio | 3.743 |
| Price to Free Cash Flow | 22.53 |
| Price | 250.48 |
| Earnings Yield | 0.93% |
| Market Cap | 37.02B |
| Operating PE Ratio | 21.62 |
| Normalized PE Ratio | 32.48 |